The new Institute aims to harness and boost immunity to tackle health puzzles - and is already supported by a generous gift from a donor
The Association for Molecular Pathology has published best practice recommendations for validating and reporting clinical circulating tumor DNA (ctDNA) or liquid biopsy assays and their related scientific publications.
A research group from Japan has developed a method to produce highly active mRNA vaccines at high purity using a unique cap to easily separate the desired capped mRNA.
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, conducted a multicenter comprehensive retrospective analysis to assess the effectiveness and safety of primary single-agent and combination therapies in treating adult patients with relapsed immune thrombocytopenia (ITP).
UCLA researchers have developed a new treatment method using a tiny nanocapsule to help boost the immune response, making it easier for the immune system to fight and kill solid tumors.
Immune cells play a key role during pregnancy, adjusting immune system response in a way that enables the fetus to develop while also protecting the parent and fetus from outside assaults like viruses.
A new, bio-inspired drug restores the effectiveness of immune cells in fighting cancer, a team led by researchers at The University of Texas at Austin has found. In mouse models of melanoma, bladder cancer, leukemia and colon cancer, the drug slows the growth of tumors, extends lifespan and boosts the efficacy of immunotherapy.
Researchers at the UCLA Jonsson Comprehensive Cancer Center have identified a new role for a protein called extracellular signal-regulated kinase (ERK) in a pathway activated by interferon-gamma that can trigger cells to self-destruct.
New analysis of the remains of victims of the 1918 influenza pandemic, which killed an estimated 50 million people worldwide, contradicts the widespread belief the flu disproportionately impacted healthy young adults.
Liquid biopsies are blood tests that can serially measure circulating tumor DNA (cell-free DNA that is shed into the bloodstream by dying cancer cells). When used in patients with advanced non-small cell lung cancer undergoing immunotherapy, they may identify patients who could benefit from treatment with additional drugs, according to a phase 2 clinical trial in the U.S. and Canada. The trial is led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy, BC Cancer and the Canadian Cancer trials Group (CCTG).
Miriam Merad, MD, PhD, an esteemed immunologist at the Icahn School of Medicine at Mount Sinai, has been elected to the National Academy of Medicine (NAM) in recognition of her pioneering contributions to the fields of immunology and cell biology.
A person’s immune response to variants of SARS-CoV-2, the virus that causes COVID-19, depends on their previous exposure – and differences in the focus of immune responses will help scientists understand how to optimise vaccines in the future to provide broad protection.
Every year, over 15,500 Australians are diagnosed with bowel cancer, and it is the second leading cause of cancer deaths in the country. Over 1,700 (one in ten) of those diagnosed are young Australians aged under 50, and this incidence is increasing.
In 2019, St. Jude lentiviral gene therapy restored the immune system in multiple infants of X-linked severe combined immunodeficiency disorder (SCID-X1) or “bubble boy disease” at the DNA level. These children can now produce functional immune systems.
As Streptococcus A cases continue to be prevalent in Queensland and internationally, a new nasal vaccine could provide long-term protection from the deadly bacteria.
ICD-10 codes are not the kind of thing that Jonathan Santoro, MD, learned about in medical school, or in his yearslong training to become a pediatric neurologist and neuroimmunologist. In fact, for most of his career he never spent any time thinking about them.
Using laboratory-grown cells from humans and genetically engineered mice, scientists at Johns Hopkins Medicine say they have evidence that modifying a specific protein in immune white blood cells known as CD8+ T cells can make the cells more robust, potentially opening the door for better use of people’s own immune system T cells to fight cancer.
Memory B cells depend on autophagy for their survival, but the protein Rubicon is thought to hinder this process. Researchers from Osaka University have discovered a shorter isoform of Rubicon called RUBCN100, which enhances autophagy in B cells.
Cal State Fullerton antibiotic-resistance researcher María Soledad Ramírez and her students have discovered a promising new therapeutic to treat Acinetobacter baumannii, a superbug commonly found in hospitals and resistant to many antibiotics.
Collaborative webinars to focus on key scientific trends and findings related to gut microbiome and nutrition, and the interaction of diet, stress and immune function.
Mount Sinai investigators have developed a new approach for treating invasive bladder cancer without the need for surgical removal of the bladder, according to a study published in Nature Medicine in September.
The notion that some level of microbial exposure might reduce our risk of developing allergies has arisen over the last few decades and has been termed the hygiene hypothesis.
Researchers at Stanford University School of Medicine, Yale University School of Medicine, and the Hospital for Special Surgery Research Institute have uncovered new details about how the immune system prevents the production of antibodies that can recognize and damage the body’s own, healthy tissues. The study, to be published September 29 in the Journal of Experimental Medicine (JEM), also reveals how this process is impaired in autoimmune disorders such as systemic sclerosis and systemic lupus erythematosus and suggests potential new strategies to treat these diseases.
The organisms that cause visceral leishmaniasis, a potentially deadly version of the parasitic disease that most often affects the skin, appear to have a secret weapon, new research suggests: They can infect non-immune cells and persist in those uncommon environments.
Treating cancer with immunotherapies known as an immune checkpoint blockade (ICB) prior to surgery (so-called neoadjuvant immunotherapy) has been a rapidly growing area of research, but the scientific community is just scratching the surface of what is possible, according to a review article co-authored by several current and former investigators from the Bloomberg~Kimmel Institute for Cancer Immunotherapy and the Johns Hopkins Kimmel Cancer Center.
Tuberculosis is old—ancient even. The infectious bacterial disease that plagued Old Testament Israelites and took down pharaohs was eventually stunted by vaccinations, antibiotics, and public health measures like isolation, but it hasn’t been cured yet. More than a million people around the world still die from TB every year.
A single-dose therapy has been developed that is highly effective against lyssavirus infection (rabies), one of the deadliest known viral infections of humans.
A Ludwig Cancer Research study has for the first time exhaustively analyzed neutrophils that reside in brain tumors, detailing how the immune cells support brain cancer survival and how they’re turned by the tumor microenvironment into enablers of malignant growth.
Below are some of the latest headlines in the Women's Health channel on Newswise.
Dr. Edward Garon, professor of medicine at the David Geffen School of Medicine at UCLA and director of the Signal Transduction and Therapeutics Program at the UCLA Jonsson Comprehensive Cancer Center, was awarded two grants totaling over $3.5 million from the National Institutes of Health to help improve outcomes for patients with early and advanced stages of non-small cell lung cancer.
Dario C. Altieri, M.D., Wistar president and CEO, will be honored by the Justinian Foundation and Society of Philadelphia for exemplifying the finest qualities of scholarship, civic leadership and integrity.
With daylight savings time ending soon, we anticipate a change in the timing of daylight hours with the sunrise occurring earlier in the morning.
The American Association of Immunologists awards thirteen principal investigators one year of salary support for trainees
People who have experienced brain fog, confusion, pain, and extreme fatigue for months or longer after being infected with the COVID-19 virus exhibit different immune and hormonal responses to the virus than those not diagnosed with long COVID.
Research conducted at Mount Sinai and Yale confirms long COVID is a biological disease by showing blood biomarkers that can predict who has it
AAI awarded four scientists funds for trips to laboratories to learn new research techniques
A study has revealed new details about a key population of immune system cells critical to successful vaccination against the pandemic virus, SARS-CoV-2.
Scientists revealed the intercellular choreography that governs protein regulation, including how unwanted proteins are tagged for degradation, an important player in human health and disease.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
A Ludwig Cancer Research study has shown that combining adoptive T cell therapy (ACT) with an innovative, personalized cancer vaccine under development at the Lausanne Branch of the Ludwig Institute for Cancer Research can benefit patients with late-stage, drug-resistant ovarian cancer.
In a study published online in CELL today, scientists at UCSF QBI, University College London and the Icahn School of Medicine at Mount Sinai reported breakthrough findings on convergent evolutionary mechanisms shared by COVID-19 variants, allowing them to overcome both adaptive and innate immune system barriers.
Researchers from Ann & Robert H. Lurie Children’s Hospital of Chicago and colleagues reported for the first time that a genetic biomarker may be able to help predict the severity of food allergy reactions.
In exploring an aspect of how killer T cells generate the raw materials required for their proliferation, a Ludwig Cancer Research study has uncovered an unexpected link between the immune cells’ metabolism, regulation of gene expression, persistence and functional efficacy that could be exploited using existing drugs to improve cancer immunotherapy.
Regular and intense aerobic exercise may reduce the risk of colorectal cancer in patients with Lynch Syndrome (LS) by improving the immune system's ability to detect and remove potentially harmful cells, according to researchers at The University of Texas MD Anderson Cancer Center.
Researchers at the University of Chicago Medicine Comprehensive Cancer Center established “proof-of-concept” for a new treatment approach that was able to effectively treat the most aggressive forms of prostate cancer.
The Cancer Research Institute and the Lustgarten Foundation Announce INSPIRE Partnership to Jointly Support Pancreatic Cancer Immunotherapy Research
As a result of vaccination or infection, our immune system produces antibodies that attach to the spike protein of SARS-CoV-2, preventing the virus from entering and replicating within cells.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
